Legend Biotech 

Yahoo Finance • 12 days ago

Legend Biotech (LEGN) Q4 2024 Earnings Transcript

Image source: The Motley Fool. Legend Biotech (LEGN) Q4 2024 Earnings Call Transcript DATE Tuesday, March 11, 2025 at 8 a.m. ET CALL PARTICIPANTS Chief Executive Officer — Ying Huang Interim Chief Financial Officer — Jessie Yeung Pres... Full story

Yahoo Finance • 13 days ago

RBC Capital Cuts PT on Legend Biotech Corporation (LEGN) to $62 From $66 – Here’s Why

Legend Biotech Corporation (NASDAQ:LEGN) is one of the best high growth healthcare stocks to buy now. RBC Capital cut the price target on Legend Biotech Corporation (NASDAQ:LEGN) to $62 from $66 on March 11, reiterating an Outperform ratin... Full story

Yahoo Finance • 25 days ago

This Fintech Stock Is Up 21% in a Year as Profits Surge, but One Fund's Nearly $300 Million Sale Cut Its Stake in Half

On February 17, 2026, HHLR Advisors reported selling 1,607,930 shares of Futu Holdings(NASDAQ:FUTU), an estimated $276.00 million transaction based on quarterly average pricing. What happened According to a Securities and Exchange Commis... Full story

Yahoo Finance • last month

Legend Biotech Q4 Earnings Call Highlights

Legend Biotech logo Key Points CARVYKTI net trade sales were about $555 million in Q4 (up 66% YoY), and management said CARVYKTI reached profitability in 2025 with the company expecting enterprise-wide profitability in 2026. The therapy... Full story

Yahoo Finance • 2 months ago

HHLR Advisors Fully Exits Baidu as AI Push Tests Its Advertising-Funded Model

Key Points HHLR Advisors, Ltd sold 1,641,000 shares of Baidu; estimated trade size was $216.23 million based on average pricing for the quarter Quarter-end position value declined by $216.23 million, reflecting both the share sale and cha... Full story

Yahoo Finance • 2 months ago

FDA Guidance on MRD Negativity Bodes Well for Legend Biotech (LEGN)

Legend Biotech (NASDAQ:LEGN) is one of the 17 biotechnology stocks with more than 50% upside. On January 20, Leonid Timashev of RBC Capital maintained an Outperform rating on Legend Biotech (NASDAQ:LEGN) and set a $66 price target. The an... Full story

Yahoo Finance • 2 months ago

Sector Update: Health Care Stocks Rise Late Afternoon

Health care stocks were higher late Thursday afternoon, with the NYSE Health Care Index adding 0.8% PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium... Full story

Yahoo Finance • 2 months ago

H.C. Wainwright Highlight Curative Potential of Legend Biotech Corporation (LEGN)’s Carvykti Despite Sales Miss

We recently compiled a list of the 20 Best Biotech Stocks Under $20 to Buy Now. The tenth stock on our list is Legend Biotech Corporation. TheFly reported on January 22 that H.C. Wainwright lowered LEGN’s price target to $50 from $60 but... Full story

Yahoo Finance • 4 months ago

Fund Discloses Increased Mineralys Bet Amid 200% Stock Run as New Drug Application Nears

Key Points New York City-based Suvretta Capital Management increased its MLYS position by 387,641 shares in the third quarter. The overall position value increased by $57.25 million from the previous period. As of September 30, Suvretta r... Full story

Yahoo Finance • 4 months ago

Here is Why Legend Biotech (LEGN) Offers Such Promising Upside

Legend Biotech (NASDAQ:LEGN) is one of the most promising mid-cap healthcare stocks under $50. As of December 19 closing, the consensus ratings for Legend Biotech (NASDAQ:LEGN) remain bullish. After a drop of almost 33% during 2025, the s... Full story

Yahoo Finance • 4 months ago

Legend Biotech to Present at the 44th Annual J.P. Morgan Healthcare Conference

Legend Biotech USA Inc. SOMERSET, N.J., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today announced that Ying Huang, Ph.D., the company’s Chief Executive O... Full story

Yahoo Finance • 4 months ago

Legend Biotech Corporation (LEGN) is an Outperform on Multiple Myeloma Treatment CARVYKTI Prospects

Legend Biotech Corp (NASDAQ:LEGN) is one of the best biotech stocks to buy according to Wall Street analysts. On December 8, RBC Capital reiterated an Outperform rating on Legend Biotech Corp (NASDAQ:LEGN) and set a $74 price target.Legend... Full story

Yahoo Finance • 4 months ago

Legend Biotech Highlights New CARVYKTI® Data in Multiple Myeloma and First-in-Human Results from Novel CAR-T Platform in Non-Hodgkin Lymphoma at ASH 2025

Triple-class exposed patients with three prior lines of therapy in CARTITUDE-1 and CARTITUDE-4 achieved a median PFS of 50.4 months after a single infusion of CARVYKTI® Translational analyses show stronger immune fitness and a more immunoc... Full story

Yahoo Finance • 4 months ago

Legend Biotech Awarded 2025 FIBA Foreign Investor of the Year by Flanders Investment & Trade

Recognizes the company’s continued investment and expansion of cell therapy manufacturing and R&D operations in Ghent, reinforcing Flanders’ position as a global biotech hub SOMERSET, N.J. and GHENT, Belgium, Nov. 27, 2025 (GLOBE NEWSW... Full story

Yahoo Finance • 5 months ago

William Blair Maintains Hold Rating on Legend Biotech (LEGN) Despite Carvykti Label Safety Concerns

Legend Biotech Corporation (NASDAQ:LEGN) ranks among the most oversold biotech stocks to invest in. On November 12, William Blair analyst Sami Corwin reiterated his Hold rating for Legend Biotech Corporation (NASDAQ:LEGN) shares. The analy... Full story

Yahoo Finance • 5 months ago

Oversold Conditions For Legend Biotech (LEGN)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the R... Full story

Yahoo Finance • 5 months ago

Legend Biotech Celebrates Official Opening of New State-of-the-Art Cell Therapy Research and Development Facility in Philadelphia

31,000-square-foot site expands Legend’s U.S. R&D footprint and strengthens its position as a global leader in cell therapy innovation The facility will support CAR-T R&D in potential oncology and immunology indications A Media Snippet a... Full story

Yahoo Finance • 6 months ago

SynOx Therapeutics Strengthens Board of Directors with Leading Experts in Commercialisation and Corporate Development Amid Continued Corporate Progress

DUBLIN and OXFORD, United Kingdom and PHILADELPHIA, Oct. 21, 2025 (GLOBE NEWSWIRE) -- SynOx Therapeutics Limited (“SynOx”), a late-stage clinical biopharmaceutical company developing emactuzumab for Tenosynovial Giant Cell Tumours (TGCT)... Full story

Yahoo Finance • 6 months ago

Legend Biotech, J&J ink Carvykti supply agreement

[Janssen Pharmaceuticals office in Brisbane, California, USA] JHVEPhoto/iStock Editorial via Getty Images * Legend Biotech (NASDAQ:LEGN [https://seekingalpha.com/symbol/LEGN]) and Johnson & Johnson's (NYSE:JNJ [https://seekingalpha.com/... Full story

Yahoo Finance • 7 months ago

Sector Update: Health Care Stocks Rise Friday Afternoon

Health care stocks advanced Friday afternoon, with the NYSE Health Care Index up 0.2% and the Health PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story